Systemic mastocytosis is a rare blood disorder in which abnormal mast cells build up in organs beyond the skin, most commonly the bone marrow, liver, spleen, and gastrointestinal tract. Mast cells are immune cells that normally help fight infections and trigger allergic responses, but in systemic mastocytosis they multiply out of control and release excessive amounts of chemical signals that cause a wide range of symptoms. The condition affects roughly 1 in 8,000 to 10,000 people in Europe, and it ranges from a mild, manageable form to a life-threatening disease depending on how much organ damage the excess mast cells cause.
What Drives the Disease
In more than 90% of cases, systemic mastocytosis traces back to a single genetic error: a mutation in the KIT gene, most often a specific change called D816V. The KIT gene produces a receptor on the surface of mast cells that normally acts like a switch, turning cell growth on only when the right signal molecule is present. The D816V mutation jams that switch in the “on” position. Mast cells with this mutation no longer need an outside signal to grow. They survive longer than they should, divide without restraint, and gradually accumulate in tissues throughout the body.
This is a somatic mutation, meaning it arises spontaneously in a person’s blood-forming cells rather than being inherited from a parent. Because the mutation happens after birth in a single cell line, it isn’t passed down to children in a predictable pattern.
Subtypes and How They Differ
Doctors classify systemic mastocytosis into subtypes based on how heavily the mast cells have infiltrated organs and whether those organs are still functioning normally. The distinction matters because it determines both treatment approach and outlook.
Non-Advanced Forms
Indolent systemic mastocytosis (ISM) is the most common subtype. Mast cells are present in the bone marrow and possibly other organs, but organ function remains intact. Most people with ISM have a normal life expectancy, based on long-term follow-up studies, and the disease rarely progresses to a more severe form. Symptoms can still be disruptive, but they stem from the chemicals mast cells release rather than from organ damage.
Smoldering systemic mastocytosis (SSM) sits one step higher. It shows heavier mast cell burden, such as bone marrow infiltration above 30% or a significantly enlarged liver or spleen, but organs are still working. SSM carries a greater risk of eventually advancing.
Advanced Forms
Aggressive systemic mastocytosis (ASM) is diagnosed when mast cell infiltration starts causing organ dysfunction. That can look like liver damage with fluid buildup in the abdomen, a spleen so enlarged it destroys blood cells, bone lesions that lead to fractures, or intestinal infiltration that prevents nutrient absorption and causes weight loss. These markers of organ failure are called C-findings, and even one is enough to classify the disease as aggressive.
Two other advanced subtypes exist. Systemic mastocytosis with an associated blood cancer means the mast cell disease occurs alongside a separate blood disorder like a myelodysplastic syndrome or a myeloproliferative neoplasm. Mast cell leukemia, the rarest and most serious form, involves very high numbers of mast cells circulating in the blood and bone marrow.
Common Symptoms
Symptoms come from two sources: the chemicals that mast cells dump into the bloodstream and the physical crowding of organs by excess mast cells. In milder forms, chemical release dominates the picture. In advanced disease, organ damage becomes the bigger problem.
Mast cells release histamine and other inflammatory mediators, which can cause flushing (sudden redness and warmth, often in the face and chest), severe itching, hives, abdominal cramping, diarrhea, nausea, and episodes of low blood pressure that feel like lightheadedness or fainting. Some people experience anaphylaxis-like reactions, with a sudden drop in blood pressure, rapid heart rate, and difficulty breathing, sometimes triggered by insect stings, alcohol, temperature extremes, or physical stress. These episodes can occur unpredictably.
Bone pain and osteoporosis are also common because the bone marrow is one of the primary sites where abnormal mast cells collect. Some people develop unexplained bone fractures before receiving a diagnosis. Brain fog, fatigue, and mood changes round out the picture for many patients, likely driven by the chronic inflammatory chemical load.
How It’s Diagnosed
Diagnosis requires meeting either one major criterion plus one minor criterion, or three minor criteria. The major criterion is finding dense clusters of mast cells (15 or more grouped together) on a bone marrow biopsy.
The minor criteria are:
- Abnormal mast cell shape. Instead of the normal round form, neoplastic mast cells appear spindle-shaped or otherwise atypical under the microscope.
- Unusual surface markers. Normal mast cells lack certain proteins on their surface. In systemic mastocytosis, the abnormal mast cells display markers called CD25, CD2, or CD30, which help pathologists confirm they are neoplastic.
- KIT D816V mutation. Detecting this specific mutation in blood or bone marrow tissue provides strong evidence.
- Elevated serum tryptase. Tryptase is a protein released by mast cells. A baseline blood level above 20 ng/mL (measured when the person is not in the middle of a reaction) counts as a minor criterion.
Because symptoms overlap with allergies, irritable bowel syndrome, anxiety disorders, and other common conditions, systemic mastocytosis is frequently missed or delayed. A serum tryptase blood test is often the first screening step when a doctor suspects the disease, since it is simple and widely available.
What Triggers Symptoms
People with systemic mastocytosis often learn through experience which situations provoke their mast cells to release chemicals in a burst. Common triggers include heat or sudden temperature changes, physical exertion, emotional stress, alcohol, certain medications (particularly nonsteroidal anti-inflammatory drugs and some anesthetics), insect venom, and spicy foods. However, reactions can also occur with no identifiable trigger, which makes the disease unpredictable and frustrating to manage.
Keeping a symptom diary helps many people identify their personal patterns. Wearing medical identification jewelry is widely recommended, especially for those who have experienced severe blood pressure drops or anaphylaxis-like episodes, so that emergency responders know to consider mast cell disease.
Treatment Options
Treatment depends entirely on the subtype. For indolent systemic mastocytosis, the goal is controlling symptoms rather than eliminating mast cells, because the disease itself has a favorable long-term outlook. Antihistamines (both the type used for allergies and the type used for acid reflux) form the backbone of daily symptom management. Additional medications can target specific symptoms like flushing, GI distress, or bone density loss. People at risk for severe reactions typically carry an epinephrine auto-injector.
For advanced forms, treatment shifts toward reducing the mast cell population. Two targeted therapies are now approved for advanced systemic mastocytosis: avapritinib and midostaurin. Both work by blocking the overactive KIT receptor that drives mast cell growth. Avapritinib is particularly notable because it was designed to specifically target the D816V mutation, and it has also become the first drug approved for indolent systemic mastocytosis, offering a cytoreductive option for patients whose symptoms aren’t adequately controlled by antihistamines alone. For the small percentage of patients whose disease lacks the D816V mutation, imatinib (a different KIT-targeting drug) is approved for aggressive cases.
In very advanced disease, stem cell transplantation may be considered, though this remains reserved for situations where other treatments have failed.
Living With the Condition
For the majority of patients who have indolent disease, systemic mastocytosis is a chronic condition that requires ongoing management but does not shorten life. Long-term studies of adults with ISM show that most maintain a normal life expectancy, and progression to advanced disease is uncommon. That said, quality of life can still be significantly affected by unpredictable flushing, GI symptoms, fatigue, and the anxiety of potential severe reactions.
Bone health deserves specific attention. Osteoporosis occurs at higher rates and at younger ages in people with systemic mastocytosis than in the general population, so bone density monitoring is a routine part of care. Vitamin D levels, calcium intake, and targeted bone-strengthening treatments may all come into play depending on individual results.
Regular monitoring with blood work (including tryptase levels) and periodic bone marrow evaluations helps track whether the disease is stable or progressing. The frequency of these check-ins varies by subtype, with indolent disease needing less frequent surveillance and smoldering or advanced disease requiring closer follow-up.